The company expects to add around 300 jobs through the facility, which will support the development and commercialization of the company’s gene therapies.
Five things for pharma marketers to know: Friday, June 5
The FDA commissioner said the agency is doing its job, not picking a fight, when it inspects drug-making facilities, and that India must take an active role for a harmonious supply chain.
More Ranbaxy woes
January 13, 2014
7:06 pm
The FDA finds problems at another plant.
Boehringer shutters problematic Ohio plant
October 7, 2013
5:12 pm
1,100 workers will lose their jobs at a plant with a history of around 40 recalls.
Business briefs: Akorn, Bayer, Lonza, plus curbing CNS drug use
August 27, 2013
5:47 pm
Akorn expands, buying Hi-Tech Pharmacal; nursing homes miss their goal to curb antipsychotic-drug use; Bayer cancer drug gets priority review; and Lonza lays off staff
Business briefs: Teva, AbbVie, Novartis, Wockhardt
July 24, 2013
7:13 pm
FDA grants Teva three years exclusivity to sell Plan B OTC for all ages; FDA gives Humira a thumbs-down for spondyloarthritis; a UK vaccine committee rejects Novartis’ meningitis B shot; and Wockhardt gets a warning letter from FDA for its manufacturing practices at an Indian plant.